Join us

Company Introduction

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With strong R&D capacity, Junshi Biosciences is at the cutting-edge of medical innovation. Our mission is to” Provide patients with world-class, trustworthy, affordable, and innovative drugs”.

We have established a globally integrated R&D process. With R&D centers in China and the US, we have the outstanding ability to discover and develop innovative biologics. Our strategic goal is “In China, For Global”.

With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small molecule drugs, ADCs, bsAb/msAb, fusion protein, nucleic acid drugs and vaccines. Five of the company’s products have received marketing authorizations in China and international markets, one of which is toripalimab, China’s domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI, and other novel therapies for the prevention and treatment of COVID-19.

We have two production bases in China with a combined fermentation capacity of 46,500L, undertaking the manufacturing of both investigational and commercial products.